The white paper on human fertilisation and embryology has reawoken the debate on research with human embryos.' A statutory licensing body will regulate in vitro fertilisation, and, as expected, experiments with cloning, the alteration of the human genome, and hybrid production will be prohibited. Nobody is surprised by these prohibitions, and as the white paper admits, it is doubtful whether such work was ever contemplated or is even possible. At issue are two alternatives for regulating research with embryos, on which parliament will take a free vote. One proposes that studies on human embryos should be banned completely, except where such embryos would be replaced during in vitro fertilisation. The second would permit embryo research up to 14 days after fertilisation-along the lines suggested by the Warnock report.'
There is consensus among doctors that the first option is unacceptable and would prevent important therapeutic developments.3 If research were banned completely, except when embryos were to be replaced into the uterus once an experiment was completed, there are grave risks that inadvertently damaged embryos might leave a defective fetus. This concern arose in Australia when embryo experimentation was temporarily banned. During that period work was conducted on freezing human eggs. Because research was restricted embryos were transferred directly to the uterus, immediately after thawing and subsequent fertilisation. Fortunately, no harm was done, and two patients successfully conceived.4 Nevertheless, it is widely thought that it would have been far safer to have fixed and studied embryos produced by such processes initially-to validate first the safety of such techniques. Such principles are just as applicable now but would be jeopardised if Parliament agreed to the first option in the white paper.
The option to conduct experimentation along lines proposed by the Warnock report is far better. The 14 day limit seems reasonable, and few scientists dissent. Apart from the fact that no researcher has managed to maintain cultured human embryos for longer than about nine days, the 14 day limit is biologically and scientifically sensible. Up to this time the embryo cannot be regarded as an individual as twinning is possible. Moreover, implantation is not fully complete, the menstrual period is still due, and pregnancy is not established. Until the primitive streak develops the embryo is undifferentiated, without organs or a nervous system. Moreover, many widely accepted methods ofcontraception-such as the coil and possibly the progesterone pill-exert their effect until this stage, and few opponents of embryo research openly advocate their prohibition.
The medical advantages of allowing research before 14 days are great. Researchers are mostly concerned to prevent genetic disease, and in the near future it will be possible to use in vitro fertilization to prevent some women at risk from giving birth to children with single gene defects. Embryo screening for Lesch-Nyhan syndrome has already been successful in a mouse model,5 and plans are afoot for similar work in patients, which could lead to diagnosis before implantation of such conditions as Duchenne muscular dystrophy and cystic fibrosis. After superovulation, when many eggs can be fertilised, biopsy specimens could be taken from embryos, a screen for specific defects conducted, and thenonlyhealthy embryos transferred to theuterus. Although this work will be validated first with in vitro fertilisation, in time a similar strategy may be used for embryos fertilised in the uterus after uterine lavage. Whether in vitro fertilisation is used or not, these methods have important advantages over chorion villus sampling and amniocentesis. Such patients would not require termination of pregnancy or repeated attempts at pregnancy in the hope offinal healthy conception. For many patients-for example, orthodox Ashkenazi Jews at risk of Tay-Sachs disease-this approach, if possible, would be religiously and morally far more acceptable than abortion. The study of antenatal detection of genetic defects is expanding rapidly, and legislation might blight the full value of such work.
Infertile women have benefited greatly from embryo research, and without it over 2000 healthy British babies born after in vitro fertilization might not be alive today. Embryo research will also improve imperfect contraceptive technology; the search for compounds that could prevent implantation or fertilisation without damaging embryos that "slip through the net" is highly important. One reason for the shortage of plastic surgeons is that during the second world war plastic surgery expanded by developing centres in specialised units divorced from other medical specialties. Subsequently plastic surgeons have been reluctant to leave these centres and join the mainstream of medicine. Thus 15 years ago when oral surgery and orthopaedics expanded greatly plastic surgery remained static.
Some authorities have, however, increased their number of plastic surgeons: for instance, the North West Thames Regional Health Authority has in the past year seen an expansion from 5-4 to 7-9 whole time equivalent plastic surgeons for-a population of 3-5 million. In 10 years' time it plans to have 10 whole time equivalents. This compares with the South West Thames Regional Health Authority, which has similar financial problems, but has only 2-3 whole time plastic surgeons for 3-2 million people and no plans for expansion.
Emergency surgery and surgery for cancer are still comprehensively provided by the NHS, although the delay in treatment in some cases is long. The wait for reconstructive surgery is now generally unacceptable and likely to get worse. Many operations in plastic surgery are thus done by other specialists, and some of the subspecialties of plastic surgery may be lost. Ultimately only cosmetic surgery may be left to plastic surgeons. In my view, the specialty is also failing in its commitment to teaching and research, which can lead only to a decline in the standards of British plastic surgery and eventually British surgery itself.
Cosmetic surgery is available on the NHS in theory if it is clinically indicated either because of a functional problem (such as excess of skin in the upper eyelid limiting the visual fields) or psychological distress. Most patients requesting cosmetic surgery have an underlying anxiety, and the plastic surgeon has discretion on which patients he accepts for treatment on the NHS and the degree of priority each is given. In truth, almost all cosmetic operations are given low priority and join the long waiting list; probably many patients now being placed on the waiting list for cosmetic surgery will never receive it. Perhaps the DHSS must declare that some operations-for example, removing tattoos, repairing split earlobes, breast augmentation, facelifts, abdominal reductions, and fat aspiration-are no longer available on the NHS. This is a line taken by the private health insurance companies and followed by state funded medical provision in Canada and Australia.
The failure of the NHS to provide an adequate service has led to a huge increase in private clinics undertaking cosmetic surgery, and such is the demand that a recent advertisement in the BMJ offered a salary of up to £150 000 a year for a surgeon to work in a cosmetic clinic. With all clinics and hospitals now able to advertise packages for specific cosmetic surgery operations we must be concerned, specifically about the unrealistic advertising, the sometimes poor selection of patients, the absence of truly informed consent, and the inability of some ofthe surgeons to manage the postoperative complications. Policing of these clinics is urgently required.
Clearly, however, the public wants cosmetic surgery and is willing to pay for it. One solution to the shortage of plastic surgeons would thus be for health authorities to employ plastic surgeons on a more part time contract. This might mean that areas of the country that have no plastic surgeon could then have one.
